A Study of AZD8233 in Participants With Dyslipidemia
Completed · Phase 2 · Has a placebo group
Conditions studied: Dyslipidaemia
In brief
AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study aims to evaluate the dose-dependent reduction in LDL-C after SC administration of multiple doses of AZD8233 as well as the associated adverse effects profile. The data generated will be used to guide choice of doses, dosing regimens, and sample sizes, as well as safety and PD monitoring in the further clinical development program.
Key facts
- Study ID
- NCT04641299
- Run by
- AstraZeneca
- People needed
- 119
- Starts
- 2020-10-28
- Expected to finish
- 2021-07-20
- Last updated by the study team
- 2022-11-18
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Roseville, California, United States
- Research Site — Inverness, Florida, United States
- Research Site — Jacksonville, Florida, United States
- Research Site — Pembroke Pines, Florida, United States
- Research Site — Meridian, Idaho, United States
- Research Site — Indianapolis, Indiana, United States
- Research Site — New Windsor, New York, United States
- Research Site — Greensboro, North Carolina, United States
- Research Site — Fargo, North Dakota, United States
- Research Site — Cincinnati, Ohio, United States
- Research Site — Aarhus N, Denmark
- Research Site — Frederiksberg, Denmark
- Research Site — Herlev, Denmark
- Research Site — Roskilde, Denmark
- Research Site — Viborg, Denmark
- Research Site — Bratislava, Slovakia
- Research Site — Bratislava, Slovakia
- Research Site — Rožňava, Slovakia
- Research Site — Trebišov, Slovakia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.